Shanghai, China

Haibin Qin

This inventor holds 1 USPTO granted patent. Top assignees: Cathay Industrial Biotech Ltd., Cathay R&d Center Co., Ltd. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haibin Qin. Retrieved from https://idiyas.com/inventor/haibin-qin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Haibin Qin: Innovator in Biotech

Introduction

Haibin Qin is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the production of dicarboxylic acids.

Latest Patents

Haibin Qin holds 1 patent. His patent involves a strain known as CAT H430, which is utilized for producing dicarboxylic acids. The methods associated with using CAT H430 are also detailed in his patent.

Career Highlights

Throughout his career, Haibin Qin has worked with prominent companies in the biotech sector. He has been associated with Cathay R&D Center Co., Ltd and Cathay Industrial Biotech Ltd. His work in these organizations has contributed to advancements in biotechnological applications.

Collaborations

Haibin Qin has collaborated with notable colleagues, including Charlie Liu and Jinxiu Liao. Their combined expertise has fostered innovation in their respective fields.

Conclusion

Haibin Qin's contributions to biotechnology, particularly through his patent on CAT H430, highlight his role as an innovator in the industry. His work continues to influence the production of essential compounds in biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…